Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00532501" target="_blank" >RIV/61388971:_____/20:00532501 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/20:43920395 RIV/00023884:_____/20:00008628

Výsledek na webu

<a href="https://journals.sagepub.com/doi/10.1177/0300060520947869" target="_blank" >https://journals.sagepub.com/doi/10.1177/0300060520947869</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/0300060520947869" target="_blank" >10.1177/0300060520947869</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure

Popis výsledku v původním jazyce

Objective This study aimed to determine the importance of biomarkers of chronic heart failure (CHF) for assessing disease severity in euvolemic stable patients. Patients and methods N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, galectin-3, cystatin-C, soluble suppression of tumorigenicity 2 (sST2), tissue type inhibitor of matrix metalloproteinase (TIMP)-1, and ceruloplasmin levels were measured in euvolemic patients with stable CHF. Severity of CHF was defined by echocardiographic and biochemical parameters. Results In 160 patients (123 men and 37 women, mean age: 65.8 +/- 12.2 years), we found strong associations between NT-proBNP and bilirubin levels (r = 0.434) and the estimated glomerular filtration rate (r = -0.321). GDF-15 and cystatin-C levels were significantly correlated with parameters of kidney function. In multivariable regression analysis, NT-proBNP levels were associated with the left ventricular ejection fraction and left ventricular end-systolic volume (coefficient of determination R-2 = 0.777). Additionally, GDF-15 levels were correlated with urea levels (R-2 = 0.742), and cystatin C levels were correlated with urea and bilirubin levels (R-2 = 0.732). Conclusion Besides NT-proBNP, GDF-15 and cystatin C are promising biomarkers for establishing the severity of disease in euvolemic patients with stable CHF.

Název v anglickém jazyce

Role of biomarkers of cardiac remodeling, myofibrosis, and inflammation in assessment of disease severity in euvolemic patients with chronic stable heart failure

Popis výsledku anglicky

Objective This study aimed to determine the importance of biomarkers of chronic heart failure (CHF) for assessing disease severity in euvolemic stable patients. Patients and methods N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor (GDF)-15, galectin-3, cystatin-C, soluble suppression of tumorigenicity 2 (sST2), tissue type inhibitor of matrix metalloproteinase (TIMP)-1, and ceruloplasmin levels were measured in euvolemic patients with stable CHF. Severity of CHF was defined by echocardiographic and biochemical parameters. Results In 160 patients (123 men and 37 women, mean age: 65.8 +/- 12.2 years), we found strong associations between NT-proBNP and bilirubin levels (r = 0.434) and the estimated glomerular filtration rate (r = -0.321). GDF-15 and cystatin-C levels were significantly correlated with parameters of kidney function. In multivariable regression analysis, NT-proBNP levels were associated with the left ventricular ejection fraction and left ventricular end-systolic volume (coefficient of determination R-2 = 0.777). Additionally, GDF-15 levels were correlated with urea levels (R-2 = 0.742), and cystatin C levels were correlated with urea and bilirubin levels (R-2 = 0.732). Conclusion Besides NT-proBNP, GDF-15 and cystatin C are promising biomarkers for establishing the severity of disease in euvolemic patients with stable CHF.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of International Medical Research

ISSN

0300-0605

e-ISSN

—

Svazek periodika

48

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

0300060520947869

Kód UT WoS článku

000563407900001

EID výsledku v databázi Scopus

2-s2.0-85089685823